{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T20:57:02Z","timestamp":1771102622891,"version":"3.50.1"},"reference-count":11,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2015,6,17]],"date-time":"2015-06-17T00:00:00Z","timestamp":1434499200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2015,8]]},"abstract":"\n This study compared the blood pressure\u2010lowering effect of ertugliflozin (1, 5, 25\u2009mg), hydrochlorothiazide (\n HCTZ<\/jats:styled-content>\n ; 12.5\u2009mg) and placebo in 194 patients with type 2 diabetes mellitus and hypertension for 4\u2009weeks using ambulatory blood pressure monitoring. Endpoints (change from baseline to week\u20094) were: 24\u2010h mean systolic blood pressure (\n SBP<\/jats:styled-content>\n ; primary); daytime, night\u2010time, seated predose\n SBP<\/jats:styled-content>\n , 24\u2010h, daytime, night\u2010time, seated predose diastolic blood pressure, 24\u2010h urinary glucose excretion and fasting plasma glucose (FPG; secondary). Safety and tolerability were monitored. Significant decreases in placebo\u2010corrected 24\u2010h mean\n SBP<\/jats:styled-content>\n (\u22123.0 to \u22124.0\u2009mmHg) were recorded for all doses of ertugliflozin (for\n HCTZ<\/jats:styled-content>\n , this was \u22123.2\u2009mmHg). Daytime, but not night\u2010time\n SBP<\/jats:styled-content>\n was consistently reduced. Ertugliflozin produced dose\u2010dependent significant decreases in\n FPG<\/jats:styled-content>\n and increases in urinary glucose excretion. No notable changes in plasma renin activity or urinary aldosterone were seen. The most common adverse events were urinary tract infection, genital fungal infection, upper respiratory tract infection and musculoskeletal pain.\n <\/jats:p>","DOI":"10.1111\/dom.12486","type":"journal-article","created":{"date-parts":[[2015,5,7]],"date-time":"2015-05-07T13:17:08Z","timestamp":1431004628000},"page":"805-808","source":"Crossref","is-referenced-by-count":56,"title":["Blood pressure\u2010lowering effect of the sodium glucose co\u2010transporter\u20102 inhibitor ertugliflozin, assessed via ambulatory blood pressure monitoring in patients with type 2 diabetes and hypertension"],"prefix":"10.1111","volume":"17","author":[{"given":"N. B.","family":"Amin","sequence":"first","affiliation":[{"name":"Pfizer Worldwide Research and Development, Pfizer Cambridge MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X.","family":"Wang","sequence":"additional","affiliation":[{"name":"Pfizer Worldwide Research and Development, Pfizer Cambridge MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. R.","family":"Mitchell","sequence":"additional","affiliation":[{"name":"Texas Center for Drug Development Inc Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. S.","family":"Lee","sequence":"additional","affiliation":[{"name":"Pfizer Worldwide Research and Development, Pfizer Cambridge MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Nucci","sequence":"additional","affiliation":[{"name":"Pfizer Worldwide Research and Development, Pfizer Cambridge MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. M.","family":"Rusnak","sequence":"additional","affiliation":[{"name":"Pfizer Worldwide Research and Development, Pfizer Cambridge MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,6,17]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.2143\/ACB.3349"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.2174\/138955710792007213"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2013.850066"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-2673"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60683-2"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-1693"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12127"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12038"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm200049r"},{"key":"e_1_2_7_11_1","unstructured":"Watson Pharma Inc.Microzide (hydrochlorothiazide USP) capsules 12.5\u2009mg prescribing information.1996."},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.005081"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdom.12486","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.12486","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T05:16:41Z","timestamp":1761887801000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.12486"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,17]]},"references-count":11,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["10.1111\/dom.12486"],"URL":"https:\/\/doi.org\/10.1111\/dom.12486","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,17]]}}}